The HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype is linked to protection from the development of type 1 diabetes (T1D). However, it is not known at which stages in the natural history of T1D development this haplotype affords protection. We examined a cohort of 3,358 autoantibody-positive relatives of T1D patients in the Pathway to Prevention (PTP) Study of the Type 1 Diabetes TrialNet. The PTP study examines risk factors for T1D and disease progression in relatives. HLA typing revealed that 155 relatives carried this protective haplotype. A comparison with 60 autoantibody-negative relatives suggested protection from autoantibody development. Moreover, the relatives with DRB1*15:01-DQA1*01:02-DQB1*06:02 less frequently expressed autoantibodies associated with higher T1D risk, were less likely to have multiple autoantibodies at baseline, and rarely converted from single to multiple autoantibody positivity on follow-up. These relatives also had lower frequencies of metabolic abnormalities at baseline and exhibited no overall metabolic worsening on follow-up. Ultimately, they had a very low 5-year cumulative incidence of T1D. In conclusion, the protective influence of DRB1*15:01-DQA1*01:02-DQB1*06:02 spans from autoantibody development through all stages of progression, and relatives with this allele only rarely develop T1D.

HLAs are antigen-presenting molecules that play a key role in mediating adaptive immune responses. HLA class I and class II molecules are restricting elements for CD8 and CD4 T-cell responses, respectively. They are encoded by polymorphic genes in the HLA complex, and a number of HLA gene variants have been linked to immune-mediated and autoimmune diseases (1,2). In type 1 diabetes (T1D), certain HLA class I and class II variants increase disease risk; these include the class I molecules encoded by A*02:01, A*24, and B39 and the class II molecules encoded by the...
HLA Protection Inhibits T1D at Multiple Stages

leading to clinically manifest diabetes. Such knowledge is of changes indicating responses to islet antigens, and the occurrence of metabolic antibodies, the development of multiple autoantibody type is protective, including the initial triggering of auto-the natural history of T1D development that this haplo-

let autoimmunity in relatives; yet, they rarely develop protection may not always prevent the triggering of is-
tcell autoantigens (7,16 previously linked to protection from T1D development

rodimer. DRB1*15:01-DQA1*01:02-DQB1*06:02 has been alleles, which together encode for the HLA-DQ6 hete-

T1D maps largely to the DQA1*01:02 and DQB1*06:02 DRB1*15:01 allele (14,15) suggests that protection from or unusual DQA1/DQB1 alleles in cis with the usual DRB1*15:01 allele (14,15) suggests that protection from T1D maps largely to the DQA1*01:02 and DQB1*06:02 alleles, which together encode for the HLA-DQ6 heterodimer. DRB1*15:01-DQA1*01:02-DQB1*06:02 has been previously linked to protection from T1D development among first-degree relatives with autoantibodies to islet cell autoantigens (7,16–19). This suggests that genetic protection may not always prevent the triggering of islet autoimmunity in relatives; yet, they rarely develop diabetes.

Nevertheless, it is not known at which stages during the natural history of T1D development that this haplotype is protective, including the initial triggering of autoantibodies, the development of multiple autoantibody responses to islet antigens, and the occurrence of metabolic changes indicating β-cell function deterioration eventually leading to clinically manifest diabetes. Such knowledge is of potential importance, as it could yield insights for devising preventive strategies against the disease. To this end, we examined the Pathway to Prevention (PTP) cohort of the Type 1 Diabetes TrialNet (TrialNet), a consortium of investigators studying the natural history, risk factors, and prevention of T1D (20). The cohort includes over 3,000 relatives of T1D patients who were found to express T1D-associated autoantibodies and are followed longitudinally with repeat oral glucose tolerance and autoantibody testing until the development of T1D. This is the first study to examine the protective influence of DRB1*15:01-DQA1*01:02-DQB1*06:02 throughout the progression to T1D.

RESEARCH DESIGN AND METHODS

Subjects

These analyses include 3,358 relatives (first to third degree) of patients with T1D who expressed T1D-associated autoantibodies and therefore are at increased risk for disease development. The relatives were identified by TrialNet, a National Institutes of Health–sponsored consortium that conducts clinical research studies in T1D patients and their relatives, including prevention trials and intervention trials following T1D diagnosis. As a control group for these PTP relatives, 60 autoantibody-negative relatives were studied; the TrialNet Coordinating Center generated randomized lists of autoantibody-negative PTP participants, which were then provided to TrialNet Clinical Centers for recruitment. All subjects signed informed consent and the study was approved by the ethics boards of all participating institutions. Demographic characteristics are shown in Table 1. Participants self-reported race and ethnicity in the screening form.

Table 1—Characteristics of PTP participants by autoantibody status

<table>
<thead>
<tr>
<th></th>
<th>AAb+ (n = 3,358)</th>
<th>AAb− (n = 60)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>18.2 ± 13.4 (n = 3,325)</td>
<td>16.6 ± 10.1 (n = 60)</td>
<td>0.23</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>21.7 ± 6.7 (n = 3,222)</td>
<td>20.7 ± 5.3 (n = 57)</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>Sex (% female)</strong></td>
<td>53.2</td>
<td>52.5</td>
<td>0.91</td>
</tr>
<tr>
<td><strong>Relation to the proband</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Offspring</td>
<td>18.5 (n = 613)</td>
<td>18.6 (n = 11)</td>
<td>0.60*</td>
</tr>
<tr>
<td>Parent</td>
<td>21.2 (n = 705)</td>
<td>15.2 (n = 9)</td>
<td></td>
</tr>
<tr>
<td>Sibling</td>
<td>52.0 (n = 1,726)</td>
<td>52.5 (n = 31)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>8.3 (n = 276)</td>
<td>13.5 (n = 8)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>(n = 38)</td>
<td>(n = 1)</td>
<td></td>
</tr>
<tr>
<td><strong>Duration of follow-up (years)</strong></td>
<td>3.0 ± 2.3</td>
<td>4.5 ± 1.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>87.1 (n = 2,872)</td>
<td>96.4 (n = 53)</td>
<td>0.04**</td>
</tr>
<tr>
<td>Other</td>
<td>12.9 (n = 424)</td>
<td>3.6 (n = 2)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>(n = 62)</td>
<td>(n = 5)</td>
<td></td>
</tr>
<tr>
<td><strong>Ethnicity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic or Latino</td>
<td>12.3 (n = 394)</td>
<td>3.6 (n = 2)</td>
<td>0.05*</td>
</tr>
<tr>
<td>Not Hispanic or Latino</td>
<td>87.7 (n = 2,806)</td>
<td>96.4 (n = 54)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>(n = 107)</td>
<td>(n = 1)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>(n = 51)</td>
<td>(n = 3)</td>
<td></td>
</tr>
</tbody>
</table>

Data are mean ± SD or %. AAb, autoantibody. *The comparison does not include “other” and “unknown.” **The comparison does not include “unknown.”
Study Design
The TrialNet PTP Study, formerly known as the Natural History Study, screens relatives of T1D patients for the presence of islet autoantibodies (20). Between 2000 and 30 September 2014, TrialNet screened approximately 140,000 relatives of patients with T1D for T1D-associated autoantibodies to glutamic acid decarboxylase 65 (GAD65A), tyrosine phosphatase-like insulinoma-associated protein (IA-2A), and insulin (mIAA). Relatives positive for any of these autoantibodies were subsequently tested for islet cell antibodies, and a subset were also tested for autoantibodies to the zinc transporter 8 (ZnT8A), as described below. Initially, all those with at least one autoantibody were prospectively followed with testing every 6 months for autoantibodies and metabolic evaluation by oral glucose tolerance test (OGTT). After 2012, some participants with single autoantibodies, who are considered at lower risk, have been followed at yearly intervals. The autoantibody-negative relatives had the same baseline testing as those who were autoantibody positive; they have been followed with autoantibody and OGTT measurements at yearly intervals. For the OGTTs, samples for plasma glucose and C-peptide measurement were obtained in the fasting state and at 30, 60, 90, and 120 min after ingestion of a 1.75 g per kilogram glucose dose (maximum: 75 g of carbohydrate). Dysglycemia was defined by a fasting glucose value ≥110 mg/dL, a 2-h value of 140–199 mg/dL, and/or a 30-, 60-, 90-min glucose value ≥200 mg/dL. The diagnosis of T1D was made according to American Diabetes Association guidelines. This required either two consecutive OGTTs in which fasting glucose values were ≥126 mg/dL and/or 2-h glucose values ≥200 mg/dL and/or HbA1c ≥6.5% and/or clinical symptoms associated with random glucose ≥200 mg/dL (21). An OGTT was repeated for diagnostic confirmation if the fasting glucose value was ≥126 mg/dL and/or the 2-h glucose value was ≥200 mg/dL. If both thresholds were not exceeded on the confirmatory OGTT, participants were followed as before. We calculated the progression scale at 6 months (PS6M), which is a measure of change in the glucose sum (from the 30-, 60-, 90-, and 120-min values of OGTTs) over a 6-month period (22). Autoantibody-positive individuals who do not progress to T1D with at least 2 years of follow-up (nonprogressors) are expected to have an average PS6M value of zero. We also evaluated early C-peptide secretion during OGTTs as defined by the 30 – 0 min difference in C-peptide levels. This measure correlates highly with the first-phase insulin response of an intravenous glucose tolerance test (23).

Laboratory Procedures
All autoantibodies were measured using standardized radioimmunoassays (24,25). Screening identified 3,358 relatives expressing at least one autoantibody. Following discovery of the ZnT8 autoantigen in 2007 (26) and the development of a specific radioimmunoassay, a subset of 1,940 autoantibody-positive relatives was tested for ZnT8A.

Samples that were positive for mIAA and/or GADA were also tested with the new electrochemiluminescence (ECL) assays (ECL-IAA and ECL-GADA, respectively) at the Barbara Davis Center Autoantibody/HLA Core Laboratory, as previously described (27–29). Both the ECL-IAA and ECL-GADA identify autoantibody responses that are more disease specific and are stronger predictors of T1D risk than the standard radioimmunoassays. ECL results were available from 931 autoantibody-positive relatives; of whom, 346 had multiple autoantibodies and 243 had T1D. Relatives were typed for HLA class II DRB1, DQA1, and DQB1 alleles using DNA-based typing with oligonucleotide probes, as previously reported (30). C-peptide levels were measured by an immunoenzymometric assay using the Tosoh AIA-600II autoanalyzer (Tosoh Bioscience, South San Francisco, CA) (31). The glucose oxidase method was used to measure the plasma glucose.

Data Analysis
The χ² tests and t tests were used to compare groups. Paired t tests were used to assess changes over time (at the beginning and end of follow-up). Cumulative incidence was determined by Kaplan-Meier analysis. Log-rank testing was used to compare cumulative incidence. Proportional hazards regression was used to assess time-dependent associations. 95% CIs are included with estimates of risk. Adjustments for multiple comparisons were not performed.

RESULTS
Characteristics at Baseline
In the PTP study, 3,358 PTP study participants were autoantibody positive and HLA typed for class II DRB1, DQA1, and DQB1 alleles. A group of 60 autoantibody-negative relatives were also typed. Key baseline characteristics are shown in Table 1 for both autoantibody-positive and autoantibody-negative relatives. Baseline characteristics for the autoantibody-positive relatives, according to the absence or presence of DRB1*15:01-DQA1*01:02-DQB1*06:02, are shown in Table 2; from here onward, we will refer to the two categories of autoantibody-positive relatives as 0602+ and 0602−, respectively. The 0602+ group had a higher mean age (P < 0.0001) with higher BMI values (P < 0.0001); sex was not significantly different. The 0602+ relatives more frequently included parents and less frequently included siblings of T1D probands (P = 0.01) (Table 2). The 60 autoantibody-negative relatives were similar in age, BMI, and sex to the autoantibody-positive relatives (Table 1); >85% of the relatives were white and not Hispanic in all the groups compared.

Frequency of DRB1*15:01-DQA1*01:02-DQB1*06:02
The frequency of DRB1*15:01-DQA1*01:02-DQB1*06:02 was higher among autoantibody-negative than that among autoantibody-positive relatives [10/60 (17%) vs. 155/3,358 (4.6%)]; the odds ratio (OR) was highly significant, consistent with protection from autoantibody development by DRB1*15:01-DQA1*01:02-DQB1*06:02 positivity (OR 0.242 [95% CI 0.120, 0.486], P < 0.001).
Frequencies of Autoantibody Positivity at Baseline

Table 3 compares baseline GADA, IA-2A, and mIAA autoantibody patterns between 0602+ and 0602− participants. The 0602+ relatives had lower proportions of autoantibody positivity for all autoantibodies: GADA (72.9% vs. 80.4%, \( P = 0.02 \)), IA-2A (17.4% vs. 35.5%, \( P < 0.0001 \)), and mIAA (29.7% vs. 38.2%, \( P = 0.03 \)). The 0602+ relatives had a higher proportion of single autoantibodies (84.5% vs. 59.0%, \( P < 0.0001 \)), most commonly GADA, and lower proportions of multiple autoantibodies (two autoantibodies, 11.0% vs. 27.9%, \( P < 0.0001 \); three autoantibodies, 4.5% vs. 13.0%, \( P < 0.0001 \)). These findings were mirrored in the smaller subset with available ZnT8A measurements (\( n = 1,940 \)); 0602+ relatives less frequently expressed ZnT8A (12.9% vs. 36.1%, \( P < 0.0001 \)) and four autoantibodies (5.9% vs. 10.5%, \( P < 0.0001 \)).

When GADA and mIAA were measured by ECL assays, ECL positivity was associated with increased risk (27,28); the proportions with ECL positivity were lower in 0602+ relatives than in 0602− relatives for GADA (21/47 [44.7%] vs. 550/883 [62.3%], \( P = 0.02 \)) and mIAA (5/47 [11.6%] vs. 305/884 [34.8%], \( P < 0.001 \)).

Progression to Multiple Autoantibodies

Figure 1A compares cumulative incidence curves between the 0602+ and 0602− relatives for progression from one to two or more autoantibodies in the entire data set (not including ZnT8A). The progression to multiple autoantibodies was lower (log-rank test, \( P = 0.001 \)) in 0602+ relatives. The 5-year conversion estimates (95% CI) for 0602+ and 0602− relatives were 19.0% (11, 31.5) and 33% (30.4, 36.7), respectively. The hazard ratio (HR) was 0.42 (0.25, 0.72). Overall, 14/131 (10.7%) 0602+ relatives and 413/1809 (21.8%) 0602− relatives converted from single to multiple autoantibody positivity on follow-up (\( P = 0.003 \), OR 0.43 [95% CI 0.24, 0.75]). Data are also shown for siblings only (Fig. 1B) (log-rank test, \( P = 0.0135 \)): the 5-year conversion estimates (95% CI) for 0602+ and 0602− relatives were 20.0% (9.8, 38.4) and 44% (38.7, 49.2), respectively. The HR was 0.40 (0.19, 0.85). Overall, 7/48 (14.6%) 0602+ relatives and 239/831 (28.8%) 0602− relatives converted from single to multiple autoantibody
positivity on follow-up ($P = 0.03$, OR 0.42 [95% CI 0.19, 0.96]). Both HRs and ORs indicate strong protection by DRB1*15:01-DQA1*01:02-DQB1*06:02 positivity from the development of multiple autoantibodies.

**Metabolic Measures at Baseline**

Table 4 compares frequencies of abnormal glucose tolerance at baseline between 0602+ and 0602− relatives with autoantibodies for those relatives who had data for all OGTT time points. The 0602+ relatives had a lower frequency of diabetic range values (fasting glucose values $\geq 126$ mg/dL and/or 2-h glucose values $\geq 200$ mg/dL) in their baseline OGTTs ($P = 0.004$). Among autoantibody-positive relatives whose glucose values were in the nondiabetic range, 0602+ relatives also had a lower frequency of dysglycemic OGTTs ($P = 0.013$). The sum of glucose (glucose sum) values from 30 to 120 min was also lower in those individuals ($509 \pm 90$ mg/dL vs. $530 \pm 109$ mg/dL, $P = 0.008$; data not shown).

In 0602+ relatives, the proportion with an impaired early C-peptide response (as defined by $30 - 20$ min C-peptide difference values <2.0 ng/mL), which correlates with the first-phase insulin response (23), was significantly lower than in 0602− relatives [10/150 (6.6%) vs. 723/3,071 (23.5%), $P < 0.001$; data not shown). The Diabetes Prevention Trial-Type 1 (DPT-1) Risk Score (DPTRS) (32), which is based on glucose and C-peptide measures along with age and BMI, was also lower in 0602+ relatives (5.5 ± 1.1 vs. 6.1 ± 1.3, $P < 0.001$; data not shown).

**Changes in Glycemia From Baseline**

The change in glucose concentrations from baseline to the 6-month visit, as indicated by the PS6M, was lower in 0602+ relatives (2.3 ± 77.2 ng/mL [$n = 75$] vs. 25.9 ± 101.9 ng/mL [$n = 1,341$], $P = 0.01$). Table 5 shows OGTT glucose values at baseline and at the 24-month (± 3 months) visit in 0602+ and 0602− relatives. The 0602− relatives showed a statistically significant increase at all OGTT time points and in the glucose sum over the 24 months; in contrast, there were no significant changes for 0602+ relatives. Moreover, 0602+ relatives showed a slight decrease in the glucose sum values from baseline, whereas there was an appreciable increase in the 0602− relatives ($P < 0.001$).

**Diagnosis of T1D**

The cumulative incidence for T1D (Fig. 2A) was much lower for 0602+ relatives ($P < 0.0001$). The 5-year T1D incidence estimates for 0602+ and 0602− relatives were 3.8% (95% CI 1.3, 10.5) and 28.5% (26.4, 30.8), respectively. The HR (95% CI) for the presence of 0602 was 0.11 (0.04, 0.29), indicating a strong protective effect of DRB1*15:01-DQA1*01:02-DQB1*06:02 positivity. Among those with dysglycemia at baseline (Fig. 2B), progression to T1D occurred less frequently in the 0602+ relatives (2/21 [9.5%] vs. 204/664 [30.7%]) (HR 0.24 [0.05, 1.03], $P = 0.05$). When we analyzed relatives with higher risk because of the presence of HLA-DR3 or -DR4 and multiple autoantibodies, protection was still evident: only 17.6% (3/17) of the 0602+ relatives have progressed to T1D.
compared with 34.1% (548/1683, \( P < 0.0001 \)) of 0602- relatives. However, only 1/131 (0.8%) 0602+ relatives with a single autoantibody developed T1D compared with the 3/17 (17.6%) 0602+ relatives with multiple autoantibodies (\( P < 0.0001 \)). Overall, only 4 of the 155 0602+ relatives developed diabetes on follow-up. The characteristics of the 0602+ individuals diagnosed with diabetes are shown in Table 6. One of the four relatives was 44.7 years of age at diagnosis and positive only for GADA. The others were all less than 16 years of age at diagnosis and had at least two autoantibodies; two subjects had high BMI values.

**Frequency of Predisposing HLA Haplotypes**

We investigated whether the presence of autoantibodies and the reduced incidence of T1D in 0602+ relatives were related to a potential lack of HLA predisposition on the other chromosome. We present data for all such relatives, and then for those with a single autoantibody at screening and on follow-up, those who acquired multiple autoantibodies on follow-up, and those who already had multiple autoantibodies at screening (Table 7). We determined the frequencies of HLA-DR3 and -DR4 haplotypes, also accounting for the contribution of the DQ locus in 0602+ and 0602- relatives. Considering that in the 0602+ group one chromosome is fixed, we compared the frequency of DR3 or DR4 haplotypes alone, so that the frequency is independent of the other chromosome. Specifically, we compared the frequency of

1. DR3, meaning any DR3 haplotype (DRB1*03) without DR4 (any DR4, DRB1*04), and more specifically the T1D-associated DR3 haplotype (DRB1*03:01-DQA1*05:01-DQB1*02:01) without any DR4; overall, 8 (0.3%) DR3-positive subjects did not have the T1D-associated DR3.

2. DR4, meaning any DR4 haplotype (DRB1*04) without DR3 (any DR3, DRB1*03), and more specifically the T1D-associated DR4 haplotypes bearing HLA-DQ8 (DRB1*04-DQA1*03:01-DQB1*03:02) without DR3; overall, 212 (8.1%) of the DR4-positive subjects did not have T1D-associated DR4-DQ8 haplotypes. Although not directly compared in the Table 7, this frequency did not differ among 0602+ and 0602- relatives (for all the groups compared \( P = 0.5-0.9 \)).

3. DR3/DR4 heterozygous genotypes, any DR3 haplotype (DRB1*03) together with any DR4 haplotype (DRB1*04), and then T1D-associated genotypes encoded by DRB1*04-DQA1*03:01-DQB1*03:02 together with DRB1*03:01-DQA1*05:01-DQB1*02:01.
The comparisons predictably show that there were differences in the frequency of DR3/DR4 genotypes among 0602+ and 0602− relatives in all subsets compared, which are explained by the fact that 0602+ relatives cannot have this genotype. There were no statistically significant differences for DR3 haplotypes in any comparison. However, the frequency of DRB1*04 haplotypes, with and without DQA1*03:01-DQB1*03:02, was lower among 0602+ relatives in comparisons of all autoantibody-positive relatives and of relatives with a single autoantibody at screening and on follow-up. Such differences in DR4 haplotypes were not observed in comparisons of relatives who multiple autoantibodies acquired on follow-up and of relatives who had multiple autoantibodies at screening.

We then compared the frequency of DRB1*04-DQA1*03:01-DQB1*03:02 (alone) in 0602+ and 0602− relatives with multiple autoantibodies (either at screening or on follow-up) and found that only 1/16 (6.2%) of the 0602+ relatives had T1D compared with 220/691 (31.8%) of 0602− relatives (P = 0.02, OR 0.14, Fisher exact test). None of the 0602+ relatives with a single autoantibody and DRB1*04-DQA1*03:01-DQB1*03:02 had developed T1D.

Finally, we compared the occurrence of T1D, multiple autoantibodies, positivity for each autoantibody, and dysglycemia at baseline and at the end of the follow-up for 0602+ relatives according to the presence of DR3 or DR4-DQ8 (DR4B1*04-DQA1*03:01-DQB1*03:02) on the other chromosome. The above parameters did not differ in this comparison, except that relatives that were 0602+ and DR4-DQ8+ were more frequently positive for multiple autoantibodies (16/45, 35.6%; P = 0.0382) (Supplementary Table 1).

**DISCUSSION**

Prior studies of islet autoantibody-positive relatives showed that those carrying the protective DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype have a very low risk of developing T1D; such relatives are unlikely to express multiple autoantibodies (7,16–19). In addition, in most 0602+ relatives, T1D did not develop even in the presence of HLA alleles that confer susceptibility on the other chromosome. However, prior studies have not examined the effect of DRB1*15:01-DQA1*03:01-DQB1*03:02 throughout the natural history of islet autoimmunity.

Previous studies have not compared the frequency of DRB1*15:01-DQA1*01:02-DQB1*06:02 between autoantibody-positive and autoantibody-negative relatives. Our cross-sectional analysis indicates that autoantibody-negative relatives carry DRB1*15:01-DQA1*01:02-DQB1*06:02 at similar frequency to that of Caucasian populations (www.allelefrequencies.net) but higher compared with autoantibody-positive relatives; moreover, we show that autoantibody development is less likely in 0602+ relatives, a finding that will require confirmation in prospective studies of autoantibody-negative relatives.

Among autoantibody-positive relatives, we show that those with DRB1*15:01-DQA1*01:02-DQB1*06:02 are less
frequently positive for each autoantibody studied, including ZnT8A, which was not included in earlier reports. The most prevalent autoantibody among 0602+ relatives was GADA, most often as a single autoantibody, which implies a lower risk of future T1D among autoantibody-positive relatives (33–36). The 0602+ relatives much less frequently expressed IA-2A, ZnT8A, and multiple autoantibodies, markers of more advanced islet autoimmunity and more rapid disease progression that typically appear closer to diagnosis.

In addition, our study is the first to show that 0602+ relatives were less often positive for GADA and IAA measured by ECL assays, which identify autoantibody responses more strongly associated with progression (27,28). Although others have observed lower proportions of multiple autoantibodies in 0602+ individuals, we provide the first prospective data showing decreased progression from single to multiple autoantibodies in 0602+ relatives.

The metabolic data also showed evidence of protection by the DRB1*15:01-DQA1*01:02-DQB1*06:02 allele. Both diabetic range and dysglycemic OGTTs were less common at baseline in the 0602+ relatives. In addition, the frequency of an impaired early C-peptide response was also lower at baseline in 0602+ relatives, indicating better β-cell function. The longitudinal assessments of changes in glycemia were consistent with a protective effect of

<table>
<thead>
<tr>
<th>Haplotypes or genotypes</th>
<th>0602+</th>
<th>0602-</th>
<th>0602+</th>
<th>0602-</th>
</tr>
</thead>
<tbody>
<tr>
<td>DRB1<em>03+, (DRB1</em>04-)</td>
<td>57/155 36.8</td>
<td>725/2,447 29.6</td>
<td>0.07</td>
<td>48/117 41.0</td>
</tr>
<tr>
<td>DRB1<em>03:01-DQA1</em>05:01-DQB1<em>02:01+, (DRB1</em>04-)</td>
<td>54/155 34.8</td>
<td>720/2,447 29.4</td>
<td>0.18</td>
<td>45/117 38.5</td>
</tr>
<tr>
<td>DRB1<em>04+, (DRB1</em>03-)</td>
<td>54/155 34.8</td>
<td>1,339/2,447 54.7</td>
<td>&lt;0.0001</td>
<td>35/117 29.9</td>
</tr>
<tr>
<td>DRB1<em>04-DQA1</em>03:01-DQB1<em>03:02+, (DRB1</em>03-)</td>
<td>45/155 29.0</td>
<td>1,136/2,447 46.4</td>
<td>&lt;0.0001</td>
<td>29/117 24.8</td>
</tr>
<tr>
<td>DRB1<em>04+ and DRB1</em>03+</td>
<td>0/155 0.0</td>
<td>755/3,203 23.6</td>
<td>&lt;0.0001</td>
<td>0/117 0.0</td>
</tr>
<tr>
<td>DRB1<em>04-DQA1</em>03:01-DQB1<em>03:02+ and DRB1</em>03:01-DQA1<em>05:01-DQB1</em>02:01+</td>
<td>0/155 0.0</td>
<td>659/3,203 20.6</td>
<td>&lt;0.0001</td>
<td>0/117 0.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Single AAb at screening → multiple AAb</th>
<th>0602+</th>
<th>0602-</th>
</tr>
</thead>
<tbody>
<tr>
<td>DRB1<em>03+, (DRB1</em>04-)</td>
<td>4/14 28.6</td>
<td>79/309 25.6</td>
</tr>
<tr>
<td>DRB1<em>03:01-DQA1</em>05:01-DQB1<em>02:01+, (DRB1</em>04-)</td>
<td>4/14 28.6</td>
<td>78/309 25.2</td>
</tr>
<tr>
<td>DRB1<em>04+, (DRB1</em>03-)</td>
<td>7/14 50.0</td>
<td>188/309 60.8</td>
</tr>
<tr>
<td>DRB1<em>04-DQA1</em>03:01-DQB1<em>03:02+, (DRB1</em>03-)</td>
<td>6/14 42.9</td>
<td>165/309 53.4</td>
</tr>
<tr>
<td>DRB1<em>04+ and DRB1</em>03+</td>
<td>0/14 0.0</td>
<td>115/413 27.8</td>
</tr>
<tr>
<td>DRB1<em>04-DQA1</em>03:01-DQB1<em>03:02+ and DRB1</em>03:01-DQA1<em>05:01-DQB1</em>02:01+</td>
<td>0/14 0.0</td>
<td>104/413 25.2</td>
</tr>
</tbody>
</table>

Average PS6M values approached zero, the value expected for nonprogres- sors, over a 6-month period. In contrast to 0602− relatives, 0602+ relatives showed essentially no change in glycemia over a 24-month period. Even among those with dysglycemia, fewer progressed to T1D.

Our study also shows that 0602+ relatives less frequently bear DR4 haplotypes, including those carrying the high-risk DQA1*03:01-DQB1*03:02 allele. Further analysis by autoantibody status reveals that this difference is true for relatives with a single autoantibody, whereas the frequency of DR4 haplotypes among relatives with multiple autoantibodies is similar among 0602+ and 0602− relatives. This suggests that the presence of DR4 among 0602+ relatives is associated with multiple autoantibodies; consistent with this, 0602+ relatives with DR4-DQ8 are more likely to have multiple autoantibodies than 0602+ relatives with DR3. However, the risk of T1D was much lower in 0602+ relatives with multiple autoantibodies and DRB1*04-DQA1*03:01-DQB1*03:02 compared with 0602− relatives with the same features. Moreover, the frequency of dysglycemia was not influenced by DR4-DQ8 or DR3 in 0602+ relatives. These observations suggest that protection that is mediated by DRB1*15:01-DQA1*01:02-DQB1*06:02 most often overcomes HLA-encoded susceptibility on the other chromosome.
However, protection is not absolute. A small minority of the 0602+ relatives had multiple autoantibodies or hyperglycemic OGTTs at baseline or during follow-up, and four relatives progressed to diabetes. Of these relatives, three had at least two autoantibodies and all carried predisposing HLA haplotypes on the other chromosome. Although limited by the small numbers of subjects available for analysis, 0602+ relatives with multiple autoantibodies have higher T1D risk compared with those with a single autoantibody, but this is estimated to be about 50% lower than the risk in 0602− relatives with multiple autoantibodies. Future studies could investigate whether these relatives have DRB1*15:01-DQA1*01:02-DQB1*06:02 with mutations or alleles that weaken the protective effect. For example, we previously reported that DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotypes carrying allele 15 at the microsatellite D6S265 (109 kb centromeric of HLA-A) confer reduced protection from T1D; this effect was observed in patients from Sweden who tended to develop disease at an older age (37). It should also be noted that among the 0602+ relatives who developed T1D in our study, the one with single GADA positivity was much older than most PTP participants.

In general, the 0602+ relatives were older and had higher BMI values than the 0602− relatives and included higher proportions of parents and lower proportions of siblings. However, as an older age and a higher BMI are likely outcomes of the protective effect of DRB1*15:01-DQA1*01:02-DQB1*06:02 from disease progression, we chose not to perform adjustments for them in our analyses. These are not true confounders but rather direct outcomes of the protective effect from T1D development. By being protected from T1D, 0602+ relatives maintaining autoantibody positivity over time are likely to be identified at an older age, with associated higher BMI values. Consistent with this, 0602+ relatives with autoantibodies were more often parents rather than siblings of T1D probands. Schisterman et al. (38) elegantly described how unnecessary adjustments could bias results; in this case, adjusting for age and BMI would be an unnecessary adjustment that would misleadingly diminish the impact of DRB1*15:01-DQA1*01:02-DQB1*06:02 positivity. Nonetheless, we analyzed siblings separately and showed that even among them, DRB1*15:01-DQA1*01:02-DQB1*06:02 protects from the acquisition of multiple autoantibodies.

The protective effect of DRB1*15:01-DQA1*01:02-DQB1*06:02 may result from interference with the immunologically mediated pathogenesis of T1D. We show that DRB1*15:01-DQA1*01:02-DQB1*06:02 markedly reduces the likelihood of autoantibody development and the spreading of autoimmune responses as determined by the number of autoantibodies. In addition, it diminishes the likelihood and the progression of glucose abnormalities, such as dysglycemia, and ultimately inhibits progression to T1D. Given the function of antigen-presenting HLA molecules, the DR or DQ molecules encoded by the protective haplotype may influence the presentation of islet cell autoantigen epitopes, a mechanism that could be operative in both the thymus and peripheral lymphoid tissues, where tolerogenic presentation of self-molecules, including T1D autoantigens, has been shown (39). Thus, potential mechanisms of protection include thymic deletion of autoreactive T cells (40), the induction of regulatory T cells, or the induction of less inflammatory responses. Models of affinity, competition, and determinant capture are consistent with these mechanisms and have been proposed to explain the genetic protection from HLA molecules (41,42). For example, the heterodimer encoded by DQA1*01:02-DQB1*06:02 displays high stability and increased ability to bind diabetogenic self-epitopes compared with predisposing molecules (43–46). These mechanisms, and ultimately whether certain HLA molecules protect from T1D or increase risk, may also be linked to variation in the density of expression of HLA-DQ molecules on the cell surface. Reports indicate that T1D-protective HLA-DQ molecules (including the DQ molecule encoded by DQA1*01:02-DQB1*06:02) are more stable than predisposing ones, and this may lead to more sustained tolerogenic presentation of islet autoantigen peptides (47).

In closing, DRB1*15:01-DQA1*01:02-DQB1*06:02 reduces the risk of developing autoantibodies, progressing from single to multiple autoantibodies, and developing dysglycemia and ultimately protects from overt diabetes. This recognition has implications for the design of recruitment strategies for prevention trials relevant to each of the stages of disease progression recently proposed (48), from genetic predisposition to the triggering of autoimmunity, the spreading of the autoimmune response, the development of dysglycemia, and later clinical disease. A treatment that mimics or replicates the protection afforded by DRB1*15:01-DQA1*01:02-DQB1*06:02 might delay or prevent T1D at any of these stages.

**Funding.** The sponsor of the trial was the Type 1 Diabetes TrialNet Pathway to Prevention Study Group. Type 1 Diabetes TrialNet Pathway to Prevention Study Group is a clinical trials network funded by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development through the cooperative agreements U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01 DK085453, U01 DK085461, U01 DK085463, U01 DK085466, U01 DK085469, U01 DK085504, U01 DK085505, U01 DK085509, U01 DK103180, U01 DK103153, U01 DK085476, and U01 DK103266. The study group is also funded by JDRF.

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or JDRF.

**Author Contributions.** A.P. and J.M.S. conducted the study, designed the analyses, analyzed the data, and wrote the manuscript. D.Bo. performed programming, provided statistical support, and analyzed data. L.Y., S.B., and A.K.S. oversaw autoantibody testing with ECL assays and HLA typing, reviewed the data, and edited the manuscript. D.Bo., H.R., L.D., C.E.-M., L.C.H., D.S., J.P.P., A.K.S. oversaw autoantibody testing with ECL assays and HLA typing, reviewed the data and the accuracy of the data analysis.
Duality of Interest. No potential conflicts of interest relevant to this article were reported.


References

4. Todd JA, Bell JI, McDevitt HO. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987;329:599–604
22. Sosenko JM, Skyler JS, Beam CA, et al.; Type 1 Diabetes TrialNet and Diabetes Prevention Trial—Type 1 Study Groups. The development and utility of a novel scale that quantifies the glycemnic progression toward type 1 diabetes over 6 months. Diabetes Care 2015;38:940–942
23. Sosenko JM, Palmer JP, Rafkin LE, et al.; Diabetes Prevention Trial-Type 1 Study Group. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 participants. Diabetes Care 2010;33:620–625
28. Yu L, Dong F, Mia D, Fouts AR, Wenzlau JM, Steck AK. Proinsulin/insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care 2013;36:2266–2270
35. Williams AJ, Lampasona V, Wyatt R, et al. Reactivity to N-terminally truncated GAD65(96-585) identifies GAD autoantibodies that are more closely associated with diabetes progression in relatives of patients with type 1 diabetes. Diabetes 2015;64:3247–3252


44. Ettinger RA, Kwok WW. A peptide binding motif for HLA-DQA1*0102/DQB1*0602, the class II MHC molecule associated with dominant protection in insulin-dependent diabetes mellitus. J Immunol 1998;160:2365–2373


46. Astill TP, Ellis RJ, Arif S, Tree T, Peakman M. Promiscuous binding of proinsulin peptides to type 1 diabetes-permissive and -protective HLA class II molecules. Diabetologia 2003;46:496–503
